Analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR – Get Rating) in a report released on Saturday. The firm set a "sell" rating on the stock.

InspireMD Stock Up 5.2 %

NYSE:NSPR opened at $1.83 on Friday. The stock has a market cap of $15.23 million, a P/E ratio of -0.82 and a beta of 1.20. The firm's fifty day simple moving average is $1.88 and its 200 day simple moving average is $2.28. InspireMD has a twelve month low of $1.68 and a twelve month high of $5.06.

InspireMD (NYSE:NSPR – Get Rating) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.59) earnings per share for the quarter. The company had revenue of $1.53 million during the quarter. InspireMD had a negative net margin of 334.66% and a negative return on equity of 54.85%.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery.

Recommended Stories

• Get a free copy of the StockNews.com research report on InspireMD (NSPR)
• MarketBeat: Week in Review 9/5 – 9/9
• Prepare For A Record-Setting Quarter For Cyber Security Stocks
• The Auto Market Is Slowly Recovering, These Stocks May Outperform
• Is DocuSign On The Verge Of A Major Reversal?
• Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.